Rheumatic diseases, referred to as rheumatic diseases, are a large group of diseases that can cause chronic pain in bones and muscles. The lack of treatment for these diseases in the past has led to prolonged and recurrent attacks, causing endless suffering to patients and being called the “undead cancer”. With the development of medical science, new drugs, new methods and new treatments have emerged, and the treatment effect has been greatly improved, and many patients can live like healthy people. Correct early diagnosis is the guarantee of treatment effect. Clinical manifestations and laboratory tests are the basis of diagnosis. The main manifestation of rheumatoid is pain and stiffness in the joints of the whole body, especially in the small joints of the hands. Stiffness is apparent in the morning (morning stiffness) and lasts for a long time, often more than one hour. The rheumatoid factor (RF) is the main laboratory indicator of rheumatoid, which is very helpful for diagnosis, with a positive rate of about 80 and a specificity of 70, which means that a positive test is neither completely sure of the diagnosis, nor can a negative test completely exclude the diagnosis, which is worth noting. In recent years, anti-cyclic citrullinated peptide antibodies (anti-CCP antibodies) have appeared almost exclusively in rheumatoid patients, improving the correctness of diagnosis and being widely used. In addition to joint pain, SLE often has fever, hair loss, rash, and hematologic and renal lesions. The most typical form of SLE is pteroidal erythema, which refers to the erythema on both cheeks without involvement of the upper lip. The typical hematologic changes are triple hypocellularity, i.e., low white blood cells, red blood cells and platelets across the board, or only one or two. Positive urine protein suggests renal involvement, and large amounts of urine protein (≥3 g daily) are diagnostic of nephrotic syndrome. The diagnosis of lupus relies on laboratory indicators such as antinuclear antibodies (ANA), anti-Sm antibodies, and anti-double-stranded DNA (ds-DNA antibodies). The typical rash in patients with dermatomyositis is an edematous purplish-red spot around the eyes, resembling drunkenness. Myositis is characterized by muscle weakness, i.e., difficulty in raising the head, difficulty in raising the upper limbs (inability to do continuous combing of the head), and difficulty in going up, turning over, standing up, and squatting. Laboratory tests are mainly for elevated creatine phosphokinase (CKP) and other muscle enzymes. The main manifestation of the strong column is stiffness and pain in the lower back and lumbar region, which slowly progresses upward straight to the neck and slightly relieves after activity. After many years of spinal ankylosis. HLA-B27 is helpful in diagnosis, but cannot be completely confirmed and ruled out. Methotrexate is the drug of choice for most rheumatoid patients and hepatotoxicity needs to be noted. In addition, leflunomide, salazosulfapyridine, and hydroxychloroquine sulfate are also commonly used. Glucocorticoids such as prednisone are only recommended for short-term application. Hydroxychloroquine sulfate and prednisone are commonly used in the treatment of systemic lupus erythematosus (SLE). Cyclophosphamide and azathioprine are often used to achieve satisfactory results in SLE combined with nephrotic syndrome. Prednisone combined with azathioprine is more effective in dermatomyositis. For patients with strong column, analgesics such as anti-inflammatory pain and salazosulfapyridine are commonly used. For patients with intractable column, newer drugs such as tumor necrosis factor antagonists are available, which are very effective but expensive. For rheumatic diseases, according to the severity of the disease, the presence or absence of comorbidities, there are many new drugs and new means to choose. In short, rheumatism is no longer an immortal cancer, but can be controlled satisfactorily.